Osteoporosis — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for osteoporosis (ICD-10-CM M80–M81). Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates the most current clinical, reimbursement, and HCC risk-adjustment resources. Use this guide to ensure accurate diagnosis and procedure code assignment, appropriate CDI query triggers, and defensible documentation for osteoporosis encounters across all settings.

🔍 1. Definition

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. Per the NIH Osteoporosis and Related Bone Diseases National Resource Center, osteoporosis is often called a “silent disease” because bone loss occurs without symptoms until a fracture occurs.

The International Osteoporosis Foundation (IOF) estimates that osteoporosis affects approximately 200 million women worldwide and causes more than 8.9 million fractures annually. In the United States, the NIH estimates that 10 million Americans have osteoporosis and another 44 million have low bone density.

Diagnostic criteria per the World Health Organization (WHO) are based on dual-energy X-ray absorptiometry (DXA) T-score measurement:

• Normal: T-score ≥ −1.0
• Osteopenia (low bone mass): T-score between −1.0 and −2.5
• Osteoporosis: T-score ≤ −2.5 at the lumbar spine, femoral neck, or total hip
• Severe osteoporosis: T-score ≤ −2.5 plus one or more fragility fractures (independent of T-score threshold)

Clinically, osteoporosis is also diagnosed when a fragility (low-trauma) fracture occurs — a fracture resulting from mechanical forces that would not normally cause fracture, such as a fall from standing height or less, regardless of the T-score value, per National Osteoporosis Foundation (NOF) guidelines.

🗂️ 2. Alternative Terminology

🩺 3. Signs & Symptoms

Osteoporosis is largely asymptomatic until a fracture occurs. When signs and symptoms are present, they typically reflect complications of bone fragility. Coders and CDI specialists should recognize the following clinical presentations that may prompt documentation queries:

• Vertebral compression fracture: Acute or chronic back pain (thoracic or lumbar), loss of height (≥ 2 cm), kyphosis (“dowager’s hump”), restricted mobility, possible radiculopathy if nerve root compression occurs.
• Hip fracture: Inability to bear weight, hip or groin pain, shortened and externally rotated limb, swelling or bruising at the hip.
• Wrist / Colles’ fracture: Pain, swelling, deformity at the distal forearm following low-energy fall on outstretched hand.
• Other fragility fractures: Rib fractures from minimal trauma (coughing, sneezing), humerus fractures, pelvic fractures — all in the absence of high-energy mechanisms.
• Chronic pain: Persistent back pain from healed or healing vertebral fractures; chronic musculoskeletal pain reducing functional status.
• Postural changes: Progressive thoracic kyphosis, loss of height over time, protruding abdomen from spinal deformity.
• Fear of falling: Psychological impact reducing ambulation and activity, contributing to deconditioning and fall risk.

🧭 4. Differential Diagnosis

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators in the medical record suggest osteoporosis and/or osteoporotic fracture, warranting documentation review or query:

🦴 6. Anatomy & Pathophysiology

Bone is a dynamic connective tissue continuously remodeled through two coupled processes: osteoclastic bone resorption and osteoblastic bone formation. In healthy adults, these processes are in balance, maintaining bone mineral density (BMD). Per StatPearls (NCBI), osteoporosis develops when bone resorption exceeds formation, leading to net bone loss.

Bone Compartments Affected

• Trabecular (cancellous) bone: Found in vertebral bodies, femoral neck, distal radius, and ribs. Highly metabolically active; preferentially affected in early (postmenopausal) osteoporosis. Accounts for most vertebral and Colles’ fractures.
• Cortical bone: Forms the outer shell of all bones and diaphysis of long bones. Predominantly lost in age-related osteoporosis and secondary causes.

Key Pathophysiological Mechanisms

• Estrogen deficiency (postmenopausal): Estrogen inhibits osteoclast activity. Loss of estrogen at menopause accelerates bone resorption dramatically; trabecular bone loss can be 3–5% per year in the first 5–7 years post-menopause, per NOF.
• Age-related bone loss (Type II / senile): Affects both sexes after age 70. Relates to decreased osteoblast activity, reduced calcium absorption, secondary hyperparathyroidism from vitamin D deficiency, and decline in growth hormone/IGF-1 axis.
• Glucocorticoid-induced osteoporosis (GIOP): Systemic corticosteroids reduce osteoblast differentiation and proliferation, increase osteocyte and osteoblast apoptosis, impair intestinal calcium absorption, and increase renal calcium excretion. Even doses ≥ 5 mg/day prednisone equivalent for ≥ 3 months significantly increase fracture risk, per ACR guidelines.
• Secondary osteoporosis mechanisms: Hyperparathyroidism increases bone resorption via PTH-mediated osteoclast activation; hyperthyroidism accelerates bone turnover; hypogonadism (males and females) removes sex hormone protection; glucocorticoid excess and malabsorption (celiac, IBD) impair calcium/vitamin D utilization.
• RANKL/OPG pathway: The RANK/RANKL/OPG axis is the central regulatory pathway of osteoclastogenesis. Denosumab (Prolia) inhibits RANKL, preventing osteoclast formation. Bisphosphonates inhibit osteoclast function by disrupting the mevalonate pathway.

Common Fracture Sites

The classic “fragility triad” of osteoporotic fractures, per UpToDate, includes:

1. Vertebral compression fractures (VCF): Most common; thoracic T7–T12 and lumbar L1–L4; often asymptomatic initially.
2. Hip fracture (femoral neck / intertrochanteric): Highest morbidity and mortality; 20–30% of patients die within one year of a hip fracture, per CDC fall prevention data.
3. Distal radius (Colles’) fracture: Often the earliest fragility fracture; sentinel event prompting DXA screening.

💊 7. Medication Impact / Treatment

Pharmacotherapy for osteoporosis should be documented with specificity in the medical record to support accurate coding, HCC capture, and prior authorization. Per Endocrine Society guidelines and the NOF, the following medication classes are used:

Antiresorptive Agents (First-line)

• Bisphosphonates (oral): Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) — oral weekly/monthly. ICD-10 code Z79.83 (long-term bisphosphonate use) should be captured. Part D benefit for oral forms.
• Bisphosphonates (IV): Zoledronic acid (Reclast) 5 mg annual infusion — HCPCS J0713; Part B-covered when administered in physician office. Ibandronate 3 mg IV quarterly — J3489.
• Denosumab (Prolia): 60 mg SC every 6 months; inhibits RANKL. HCPCS J0897 (1 mg = $2.98; 60 mg = ~$178.80 per injection). Critical documentation: Discontinuation without transitioning to a bisphosphonate causes rebound vertebral fractures. Always document reason for discontinuation.
• Raloxifene (Evista): SERM — reduces vertebral fracture risk; no parenteral administration; oral daily. No specific HCPCS for physician administration; Part D oral.

Anabolic Agents (For High-Risk / Established Osteoporosis)

• Teriparatide (Forteo): Recombinant PTH(1-34); 20 mcg SC daily for up to 2 years. HCPCS J3110 (may apply; verify FY2026 assignment). Requires prior authorization; high cost.
• Abaloparatide (Tymlos): PTHrP analog; 80 mcg SC daily for up to 2 years. HCPCS J3484. Reduces vertebral and nonvertebral fracture risk.
• Romosozumab (Evenity): Anti-sclerostin antibody; 210 mg SC monthly for 12 months. Dual mechanism (anabolic + antiresorptive). Must transition to antiresorptive therapy after 12 months. High cardiovascular risk caveat — document MI/stroke history.

Supportive Therapies

• Calcium and Vitamin D supplementation: Foundational therapy; E55.9 (vitamin D deficiency) and E83.51 (hypocalcemia) should be coded when documented. Calcium 1,000–1,200 mg/day; Vitamin D 800–1,000 IU/day.
• Hormone therapy (HRT): Estrogen ± progestogen for postmenopausal women; reduces bone loss; FDA-approved for prevention but not as first-line for osteoporosis treatment due to breast cancer risk.
• Calcitonin (Miacalcin): Less commonly used; primarily for pain management in acute VCF.

Steroid-Induced Osteoporosis — Drug Interaction Alert

Patients on long-term systemic glucocorticoids (Z79.52) require co-prescription of bisphosphonates per ACR GIOP guidelines. Both Z79.52 and the osteoporosis diagnosis (M81.8 or M80.8xx) should be coded. Failure to document and code steroid-induced osteoporosis is a significant CDI opportunity.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

Osteoporosis codes are found in Chapter 13: Diseases of the Musculoskeletal System and Connective Tissue (M00–M99), specifically subcategory M80–M81, per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting. Key guidelines include:

Guideline 1: Category M80 vs. M81

• M80 is used when osteoporosis IS associated with a current pathological fracture. A pathological fracture is a break in a bone that is diseased (weakened) and therefore breaks with minimal or no trauma.
• M81 is used when osteoporosis exists but there is NO current pathological fracture.
• A code from M80, not a traumatic fracture code, should be used for any patient with known osteoporosis who suffers a fracture, even if the patient had a minor fall or trauma, if that fall or trauma would not ordinarily have caused a fracture in a non-diseased bone.

Guideline 2: 7th Character Requirements for M80

Codes in subcategory M80 require a 7th character to indicate the episode of care:

Guideline 3: Site and Laterality

Many M80 codes require a 6th character for site and laterality:

• The site identifies the specific bone or region (shoulder, humerus, forearm, hand, femur/hip, lower leg, ankle/foot, vertebra)
• Laterality is required for limb fractures (1=right, 2=left, 9=unspecified)
• Vertebral fractures require additional specificity characters for cervical (A), thoracic (B), lumbar (D/4)

Guideline 4: Sequencing — Primary vs. Secondary Osteoporosis

• When osteoporosis is due to an underlying condition (secondary osteoporosis), the underlying cause is sequenced first and the osteoporosis code (M81.8 or M80.8xx) second, per ICD-10-CM Etiology/Manifestation convention.
• Examples: Long-term steroid use (Z79.52) → M81.8; Cushing’s disease (E24.0) → M81.8; Hyperparathyroidism (E21.0) → M81.8
• Exception: When the encounter is for the fracture itself, M80.8xx may be sequenced as the principal/first-listed diagnosis.

Guideline 5: Personal History vs. Current Fracture

• Z87.310 (personal history of healed osteoporosis fracture) is used ONLY when the fracture has healed and is no longer under active treatment. This code does NOT map to an HCC.
• When a patient is still receiving care for an osteoporotic fracture, M80.x with the appropriate 7th character (D, G, K, P) is correct — not Z87.310.

Guideline 6: MS-DRG Assignment

Osteoporotic fractures assigned to the appropriate M80 codes will map to MS-DRGs based on the fracture site and complications:

• Hip/femur fracture (M80.051xA–M80.062xA): MS-DRG 480–482 (Hip & Femur Procedures) when surgical; MS-DRG 536–538 (Fractures of Hip & Pelvis) when non-surgical
• Vertebral fracture (M80.0AxA): MS-DRG 551–553 (Medical Back Problems)
• Presence of MCC/CC significantly affects DRG weight and reimbursement

🔢 9. ICD-10-CM Code Set (FY2026)

M80 — Osteoporosis with Current Pathological Fracture

M81 — Osteoporosis without Current Pathological Fracture

Related / Additional Codes (Assign with M80/M81 as appropriate)

🔎 10. Indexing

The following alphabetic index entries from the FY2026 ICD-10-CM Alphabetic Index assist in locating the correct osteoporosis code:

🏥 11. CPT (2026)

🧾 12. HCPCS (2026)

📚 13. AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic guidance is relevant to osteoporosis coding. Coders should verify the most current issue for any updates:

💰 14. HCC / Risk Adjustment (v28)

Under the CMS-HCC model version 28 (fully phased in for payment year 2026), osteoporosis-related diagnoses map as follows:

✍️ 15. CDI Query Templates

All query templates below follow ACDIS/AHIMA query guidelines: non-leading, multiple-choice format, with clinical context provided.

🧑‍⚕️ 16. Treatments (Clinical)

Clinical management of osteoporosis is multifaceted, incorporating lifestyle modification, pharmacological therapy, and fracture prevention strategies. Per Endocrine Society 2019 guidelines and updated NOF treatment guidelines:

Non-Pharmacological Interventions

• Fall prevention programs: Balance training (e.g., tai chi), physical therapy, home safety assessment, footwear optimization, vision correction — directly reduces fracture incidence.
• Weight-bearing and resistance exercise: 30 minutes most days; improves BMD modestly, improves muscle strength and proprioception significantly.
• Calcium and Vitamin D optimization: Dietary calcium 1,000–1,200 mg/day; Vitamin D 800–1,000 IU/day for adults ≥ 50; serum 25-OH Vitamin D target ≥ 30 ng/mL.
• Smoking cessation: Smoking directly accelerates bone loss (estimated −3% to −5% BMD loss at hip).
• Alcohol reduction: Limit to < 2 drinks/day; alcohol increases fall risk and impairs bone formation.
• Vertebral augmentation (vertebroplasty / kyphoplasty): For painful osteoporotic VCF unresponsive to ≥ 4–6 weeks conservative management; CPT 22510–22515. NASS guidelines support kyphoplasty for acute painful VCF.
• Hip protectors: Padded undergarments that absorb hip impact; evidence mixed for community-dwelling patients but supported for high-risk nursing home residents.

Pharmacological Treatment Thresholds

Per NOF, pharmacotherapy is recommended when:

• DXA T-score ≤ −2.5 at lumbar spine or hip
• DXA T-score between −1.0 and −2.5 (osteopenia) plus FRAX 10-year hip fracture probability ≥ 3% OR major osteoporotic fracture probability ≥ 20%
• Any prior hip or vertebral fracture (regardless of T-score)

Monitoring

• Repeat DXA every 1–2 years to monitor treatment response; significant change defined as ≥ 3–5% change (exceeds least significant change for the machine)
• Bone turnover markers (CTX, P1NP) can be used at 3–6 months to confirm pharmacological response
• Drug holidays (bisphosphonates): After 3–5 years of oral bisphosphonate or 3 years IV zoledronic acid, reassess fracture risk; low-risk patients may take a drug holiday (stop therapy) while monitoring continues
• Rare but serious complications to monitor: Atypical femoral fracture (AFF) — code M84.55x; Osteonecrosis of the jaw (ONJ) — code M87.180 — associated with long-term bisphosphonate or denosumab use

🎓 17. Patient Education / Summary

The following summary is intended to assist CDI and clinical staff in patient education, reinforcing documentation accuracy and care coordination for osteoporosis management:

Key Facts for Patients and Families

• Osteoporosis is preventable and treatable. Early diagnosis through DXA screening, combined with medication and lifestyle changes, can significantly reduce fracture risk.
• Who should be screened: Per USPSTF guidelines: All women age 65 and older; postmenopausal women under 65 with increased risk factors; men should discuss screening with their provider starting at age 70. Code Z13.820 for screening encounter.
• DXA scan information: The DXA (bone density test) is a low-radiation X-ray that measures bone mineral density. Scores are reported as T-scores. A T-score of −2.5 or lower means osteoporosis.
• Medication adherence is critical: Oral bisphosphonates (alendronate, risedronate) must be taken correctly — on an empty stomach, with a full glass of water, remain upright for 30 minutes — to be effective and minimize esophageal irritation.
• Do not stop denosumab (Prolia) without talking to your doctor. Stopping this medicine suddenly can cause multiple spinal fractures. A different bone medicine must be started when stopping Prolia.
• Fall prevention is as important as medication. Most osteoporotic fractures are caused by falls. Remove home hazards, use grab bars, ensure adequate lighting, and review all medications that cause dizziness.
• Vitamin D and Calcium: Many patients with osteoporosis are deficient in vitamin D and calcium. These should be measured and replaced as needed — lab testing supports E55.9 or E83.51 coding when deficiencies are present.

Documentation Reminders for Clinical Staff

• Always document “osteoporosis” explicitly in the assessment/plan when a DXA T-score ≤ −2.5 or a fragility fracture is present — do not rely on lab/radiology reports alone.
• Specify fracture site and laterality (right vs. left) for all pathological fractures — this affects ICD-10 code assignment and HCC capture.
• Note whether a fracture is new (initial encounter, 7th char A), healing (subsequent, 7th char D), or the old fracture is now a sequela (7th char S).
• Document underlying causes of secondary osteoporosis (steroids, hyperparathyroidism, malabsorption, hormonal deficiency) — these support additional codes and may have independent HCC value.
• Document Vitamin D and calcium levels if tested — supports clinical coding of deficiency conditions.

Coding Summary

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)